The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Commission seeks Hospital Pharmacists with Pharmacovigilanceand Advanced Therapy expertise
Healthcare Professionals with expertise in Pharmacovigilance and Advanced Therapies are being sought for membership of two committees of the European Medicines Agency (EMA).
On Monday 9th July the European Commission relaunched its call for expressions of interest from representatives of patient and healthcare-professional organisations who wish to sit on the EMA’s Committee for Advanced Therapies (CAT) or the Pharmacovigilance Risk Assessment Committee (PRAC).
The call was first launched in September 2011. It has been launched again at the request of the European Parliament because the initial call led to a low number of expressions of interest. The new call aims to widen the choice of representatives.
All expressions of interest will be assessed by the European Commission. As for all members of the Agency's committees, the representatives will not be permitted to have any financial or other interests in the pharmaceutical industry that could affect their impartiality, and will be required to make an annual declaration of their interests. All applicants are also required to submit a completed declaration of interest form with their expression of interest.
The deadline for expressions of interest is 1 October 2012.
It should be noted that membership of the PRAC and CAT committees is not remunerated at the current time but expenses will be paid.
More information here.